• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国五个肾脏单位成年原发性局灶节段性肾小球硬化患者的治疗与转归

Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units.

作者信息

Stirling C M, Mathieson P, Boulton-Jones J M, Feehally J, Jayne D, Murray H M, Adu D

机构信息

Glasgow Royal Infirmary, Glasgow, UK.

出版信息

QJM. 2005 Jun;98(6):443-9. doi: 10.1093/qjmed/hci072. Epub 2005 May 6.

DOI:10.1093/qjmed/hci072
PMID:15879445
Abstract

BACKGROUND

Focal segmental glomerulosclerosis (FSGS) is the least studied of the causes of idiopathic nephrotic syndrome, and there are few specific guidelines for treatment.

AIM

To review data from five UK renal units to investigate whether adult patients with FSGS were treated uniformly, and to examine the effect of treatment on proteinuria and survival.

DESIGN

Retrospective record review.

METHODS

We examined electronic records of patients with idiopathic FSGS for information on baseline clinical parameters, treatment regimens and outcomes.

RESULTS

Of 136 patients with primary FSGS and nephrotic range proteinuria, 76 (56%) were treated with prednisolone and of this group, 59% were treated with additional immunosuppression. Among the treated patients, the total remission rate (complete and partial) was 67%, and one hospital achieved a remission rate of 80%. Treated patients had a significantly higher remission rate than those who were not treated. Remission was associated with a 5-year survival off dialysis of 94%, compared with 53% if remission was not achieved. Baseline serum creatinine and remission were independently associated with survival off dialysis in a multivariate Cox proportional hazards model.

DISCUSSION

Patients with primary FSGS and nephrotic range proteinuria, who are treated with corticosteroids, are more likely to enter remission than those who are not treated. Remission rates of up to 80% can be achieved with prolonged treatment, and remission is an independent predictor of survival off dialysis. Patients who do not achieve remission have a poor prognosis. Further clarification of optimal treatment regimens requires additional, prospective studies.

摘要

背景

局灶节段性肾小球硬化症(FSGS)是特发性肾病综合征病因中研究最少的,且几乎没有具体的治疗指南。

目的

回顾来自英国五个肾脏单位的数据,以调查FSGS成年患者的治疗是否统一,并研究治疗对蛋白尿和生存率的影响。

设计

回顾性记录审查。

方法

我们检查了特发性FSGS患者的电子记录,以获取基线临床参数、治疗方案和结局的信息。

结果

在136例原发性FSGS且蛋白尿达到肾病范围的患者中,76例(56%)接受了泼尼松龙治疗,其中59%还接受了额外的免疫抑制治疗。在接受治疗的患者中,总缓解率(完全缓解和部分缓解)为67%,有一家医院的缓解率达到了80%。接受治疗的患者缓解率明显高于未接受治疗的患者。缓解与透析脱机后的5年生存率为94%相关,而未实现缓解者为53%。在多变量Cox比例风险模型中,基线血清肌酐和缓解与透析脱机后的生存独立相关。

讨论

原发性FSGS且蛋白尿达到肾病范围的患者,接受皮质类固醇治疗比未接受治疗的患者更有可能进入缓解期。延长治疗可实现高达80%的缓解率,且缓解是透析脱机生存的独立预测因素。未实现缓解的患者预后较差。需要更多的前瞻性研究来进一步明确最佳治疗方案。

相似文献

1
Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units.英国五个肾脏单位成年原发性局灶节段性肾小球硬化患者的治疗与转归
QJM. 2005 Jun;98(6):443-9. doi: 10.1093/qjmed/hci072. Epub 2005 May 6.
2
Individualized scheme of immunoadsorption for the recurrence of idiopathic focal segmental glomerulosclerosis in the graft: a single center experience.移植肾特发性局灶节段性肾小球硬化复发的个体化免疫吸附方案:单中心经验
Ren Fail. 2015 Jun;37(5):777-83. doi: 10.3109/0886022X.2015.1015366. Epub 2015 Feb 26.
3
Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study.特发性局灶节段性肾小球硬化的免疫抑制治疗:一项五年随访研究。
Nephron Clin Pract. 2006;104(2):c75-82. doi: 10.1159/000093993. Epub 2006 Jun 19.
4
Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.塌陷型与未另行指定的局灶节段性肾小球硬化患者的肾脏存活率比较。
Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1752-1759. doi: 10.2215/CJN.13091215. Epub 2016 Jul 21.
5
Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.膜性肾病的临床和形态学预后因素:局灶节段性肾小球硬化的意义
Am J Kidney Dis. 2003 Jan;41(1):38-48. doi: 10.1053/ajkd.2003.50015.
6
Primary FSGS in Nephrotic Adults: Clinical Profile, Response to Immunosuppression and Outcome.成人肾病综合征中的原发性局灶节段性肾小球硬化:临床特征、免疫抑制反应及预后
Nephron. 2016;132(2):81-5. doi: 10.1159/000442999. Epub 2016 Jan 23.
7
Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.他克莫司治疗对类固醇和环磷酰胺耐药的成人肾病综合征且肾小球滤过率正常或轻度降低者。
Am J Kidney Dis. 2009 Jul;54(1):51-8. doi: 10.1053/j.ajkd.2009.02.018. Epub 2009 May 5.
8
Clinical course of primary focal segmental glomerulosclerosis (FSGS) in Turkish children: a report from the Turkish Pediatric Nephrology FSGS Study Group.土耳其儿童原发性局灶节段性肾小球硬化(FSGS)的临床病程:来自土耳其儿科肾脏病FSGS研究组的报告
Turk J Pediatr. 2010 May-Jun;52(3):255-61.
9
The treatment of idiopathic focal segmental glomerulosclerosis in adults.成人特发性局灶节段性肾小球硬化的治疗
Adv Chronic Kidney Dis. 2014 Sep;21(5):434-41. doi: 10.1053/j.ackd.2014.03.016.
10
Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants.成人肾病综合征中的局灶节段性肾小球硬化:组织学亚型的临床表现、预后及对治疗的反应
J Am Soc Nephrol. 2004 Aug;15(8):2169-77. doi: 10.1097/01.ASN.0000135051.62500.97.

引用本文的文献

1
Comparison and prognostic analysis of focal segmental glomerulosclerosis patients with or without nephrotic syndrome at onset.发病时伴有或不伴有肾病综合征的局灶节段性肾小球硬化患者的比较及预后分析。
BMC Nephrol. 2025 Jul 5;26(1):353. doi: 10.1186/s12882-025-04292-z.
2
Clinical course and outcome of adult patients with primary focal segmental glomerulosclerosis with kidney function loss on presentation.初诊时伴有肾功能丧失的成人原发性局灶节段性肾小球硬化症患者的临床病程及预后
World J Nephrol. 2024 Dec 25;13(4):98932. doi: 10.5527/wjn.v13.i4.98932.
3
Renal survival and treatment of adult patients with Primary Focal Segmental glomerulosclerosis: A historical cohort study of the National Greek Registry.
成人原发性局灶节段性肾小球硬化症患者的肾脏存活率及治疗:希腊国家登记处的一项历史性队列研究
PLoS One. 2024 Dec 18;19(12):e0315124. doi: 10.1371/journal.pone.0315124. eCollection 2024.
4
Focal segmental glomerulosclerosis (FSGS) in pregnancy: The case of a 27-year-old woman with nephrotic syndrome at 22 weeks of gestation.妊娠期间的局灶节段性肾小球硬化症(FSGS):一名27岁女性在妊娠22周时患肾病综合征的病例。
SAGE Open Med Case Rep. 2024 Nov 13;12:2050313X241300658. doi: 10.1177/2050313X241300658. eCollection 2024.
5
Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis.蛋白尿作为局灶节段性肾小球硬化症临床试验的终点指标
Am J Kidney Dis. 2025 May;85(5):610-617. doi: 10.1053/j.ajkd.2024.08.011. Epub 2024 Oct 23.
6
A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING).一项随机、双盲、安慰剂对照的 III 期双臂(1:1 比例)试验,旨在评估利妥昔单抗治疗 MCD/FSGS 患者新发或复发的特发性肾病综合征(NS)的疗效、安全性、成本和成本效益(TURING)。
BMC Nephrol. 2024 Aug 7;25(1):253. doi: 10.1186/s12882-024-03576-0.
7
Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort.德国慢性肾脏病队列中成人局灶节段性肾小球硬化症的长期预后
Clin Kidney J. 2024 Apr 27;17(7):sfae131. doi: 10.1093/ckj/sfae131. eCollection 2024 Jul.
8
Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis.一项评估二甲双胍激活AMP激酶治疗局灶节段性肾小球硬化的2期双盲安慰剂对照随机试验的原理与设计
Kidney Int Rep. 2024 Feb 13;9(5):1354-1368. doi: 10.1016/j.ekir.2024.02.006. eCollection 2024 May.
9
The outcomes of patients with kidney failure due to focal segmental glomerulosclerosis (FSGS) in Australia and New Zealand: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA).澳大利亚和新西兰局灶节段性肾小球硬化症(FSGS)导致肾衰竭患者的结局:一项使用澳大利亚和新西兰透析和移植登记处(ANZDATA)的队列研究。
PLoS One. 2023 Nov 2;18(11):e0293721. doi: 10.1371/journal.pone.0293721. eCollection 2023.
10
High Rate of Mutations of Adhesion Molecules and Extracellular Matrix Glycoproteins in Patients with Adult-Onset Focal and Segmental Glomerulosclerosis.成人起病的局灶节段性肾小球硬化患者中黏附分子和细胞外基质糖蛋白的高突变率
Biomedicines. 2023 Jun 20;11(6):1764. doi: 10.3390/biomedicines11061764.